Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on May 8, 2025

Ainnocence Unveils Core Challenges Undermining AI-Driven Small-Molecule Drug Discovery
How current methodologies fail to address critical challenges in early stage drug discovery. SAN FRANCISCO, CA, UNITED STATES, May 8, 2025 /EINPresswire.com/ -- Ainnocence, a leader in next-generation AI drug-discovery solutions, today released a …

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update
-- Company delivers on mission to transform women’s health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system approval pending in Europe) -- ATLANTA, May 08, …

Nova Leap Health Corp. Posts Q1 2025 Results
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, May 08, 2025 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing home health care organization, is …

VitalHub Reports First Quarter 2025 Results
Annual Recurring Revenue (ARR)⁽¹⁾ up 54% YoY to $73.7 million Total Revenue up 42% YoY to $21.7 million Adjusted EBITDA⁽¹⁾ up 39% YoY to $5.6 million TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX: …

Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that management plans to participate in the following upcoming investor conferences: Bank of America Securities 2025 Health Care Conference on …

Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
Hopewell, New Jersey, May 08, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally …

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - - Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and …

17th Gulf Heart Association Conference
17th Gulf Heart Association Conference, November 20-22, Doha, Qatar DOHA, QATAR, May 8, 2025 /EINPresswire.com/ -- The Gulf Heart Association (GHA) is excited to announce the upcoming 17th GHA Conference, set to be held in Doha, Qatar from November 20th …

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets
Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone) KANSAS CITY, Kan., May 08, 2025 (GLOBE NEWSWIRE) -- Cingulate …

BioSyent Schedules First Quarter Earnings Release for May 15, 2025
MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2025 on Thursday, May 15, 2025 after market hours. A presentation …

Galecto Reports First Quarter 2025 Operating and Financial Results
BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter …

BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025
MELVILLE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced …

Theriva Biologics Announces Closing of $7.5 Million Public Offering
ROCKVILLE, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, …

17th Gulf Heart Association Conference
DOHA, QATAR, May 8, 2025 /EINPresswire.com/ -- مايو 20258 مؤتمر جمعية القلب الخليجية السابع عشر الدوحة، قطر – يسرّ جمعية القلب الخليجية (GHA) أن تعلن عن انطلاق مؤتمرها في نسخته السابعة عشرة. ومن المزمع انعقاد المؤتمر في الدوحة، قطر، خلال الفترة من 20 …

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson’s disease in Q4 2025 Strengthened balance sheet with recent financing Advancing innovative POZ Platform across multiple therapeutic modalities Two new seasoned …

Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results …

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025 Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for …

PacBio Announces First Quarter 2025 Financial Results
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results: Q1 2025 Q1 2024 Revenue $37.2 million $38.8 million Instrument revenue $11.0 million …

Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025
GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that …

AMN Healthcare Announces First Quarter 2025 Results
Quarterly revenue of $690 million; GAAP loss of ($0.03)/share and adjusted EPS of $0.45 DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations …